Zimbabwe’s health authorities began administering a long-acting injectable HIV prevention drug, lenacapavir, on Thursday, February 19, marking one of the first national rollouts of the medication globally. The initiative aims to curb new HIV infections in the southern African nation.
Health Minister Douglas Mombeshora stated the program, financially supported by the United States and the Global Fund, will initially focus on over 46,000 individuals identified as being at high risk of contracting HIV. The rollout will occur across 24 sites nationwide.
The arrival of lenacapavir in Zimbabwe represents a significant step in HIV prevention strategies, offering a new option beyond daily oral medication. According to reports, the drug provides long-lasting protection with fewer doses required, potentially improving adherence and reducing the burden on healthcare systems.
Kenya also recently received its first shipment of lenacapavir, receiving 21,000 starter doses on February 17. The Kenyan Ministry of Health plans a phased rollout beginning in March 2026, initially targeting 15 high-burden counties. Subsequent phases will expand coverage nationally, contingent upon service preparedness and a reliable supply of the medication.
The rollout in Zimbabwe follows similar initiatives in other parts of the world, as global health organizations seek to leverage long-acting injectable formulations to combat the HIV epidemic. The drug, developed by Gilead Sciences, has shown promising results in clinical trials, demonstrating high efficacy in preventing HIV acquisition.
While the initial funding for Zimbabwe’s program is secured, the long-term sustainability of the rollout will depend on continued financial support and the integration of lenacapavir into the country’s existing healthcare infrastructure. The Ministry of Health has not yet announced details regarding ongoing supply chains or future funding mechanisms.
